Glen Mills, PA, United States of America

Eric Routhier

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 3 EPO patents. Top assignee: Morphotek, Inc.. Active years: 2008-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric Routhier. Retrieved from https://idiyas.com/inventor/eric-routhier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 118(Granted Patents)

Company Filing History:

11 out of 65

Morphotek, Inc.

patents

Years Active: 2008-2018

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10023632 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2018-07-17),

2. 9422367 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2016-08-23),

3. 9115197 - Anti-mesothelin antibodies (2015-08-25),

4. 8658173 - Anti-mesothelin antibodies (2014-02-25),

5. 8623364 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2014-01-07),

6. 8481703 - Anti-mesothelin antibodies (2013-07-09),

7. 8318168 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2012-11-27),

8. 8206710 - Anti-mesothelin antibodies (2012-06-26),

9. 7741450 - Antibodies to GM-CSF (2010-06-22),

10. 7592426 - Anti-mesothelin antibodies (2009-09-22),

11. 7332584 - Antibodies that specifically bind PMS2 (2008-02-19),

Title: Inventor Eric Routhier: Pioneering Advances in Therapeutic Antibodies

Introduction

Eric Routhier, an accomplished inventor based in Glen Mills, PA, USA, has made significant contributions to the field of biomedicine through his innovative work. With a remarkable portfolio of 11 patents, Routhier focuses on the development of advanced therapeutic methods that target critical disease processes.

Latest Patents

Among his latest innovations are patents for Antigenic GM-CSF peptides and innovative antibodies to GM-CSF. These patents detail hybridoma lines that secrete human monoclonal antibodies characterized by their high binding specificity and biological activity. Notably, these antibodies exhibit potent neutralizing activity against granulocyte-macrophage colony-stimulating factor. Routhier's work provides essential methodologies for generating these hybridoma lines and identifies various target antigens and epitopes. The therapeutic implications of these inventions are significant, providing potential treatment avenues for cancer, infectious diseases, and autoimmune disorders.

Career Highlights

Eric Routhier has built a noteworthy career at Morphotek, Inc., where he has utilized his expertise in antibody development and therapeutic applications. His role at the company has been pivotal in advancing the research and development of monoclonal antibodies that can improve treatment outcomes for patients.

Collaborations

Routhier’s work is further enhanced by collaboration with prominent colleagues, including Luigi Grasso and Nicholas C Nicolaides. Together, they contribute to a dynamic research environment that fosters innovation and supports the mission of creating effective therapeutic solutions.

Conclusion

In summary, Eric Routhier stands out as a key innovator in the field of therapeutic antibodies. With a strong patent portfolio and active collaborations, he continues to advance medical technology, offering hope for effective treatments in challenging health conditions. His work is a testament to the significant impact that dedicated inventors can have on healthcare and patient well-being.

Profile summary based on public USPTO records.